GYRE THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
GYRE$4.23-9.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues | $116,588 | $105,757 |
| Operating expenses: | ||
| Cost of revenues | 5,416 | 3,884 |
| Selling and marketing | 65,179 | 57,511 |
| Research and development | 13,698 | 12,024 |
| General and administrative | 20,804 | 16,109 |
| Loss on disposal of assets, net | 4 | 66 |
| Total operating expenses | 105,101 | 89,594 |
| Income from operations | 11,487 | 16,163 |
| Other income (expenses): | ||
| Interest income, net | 1,747 | 1,547 |
| Other expense, net | (1,505) | (1,659) |
| Change in fair value of warrant liability | 2,707 | 7,167 |
| Income before income taxes | 14,436 | 23,218 |
| Provision for income taxes | (4,556) | (5,320) |
| Net income | 9,880 | 17,898 |
| Net income attributable to noncontrolling interest | 4,853 | 5,813 |
| Net income attributable to common stockholders | $5,027 | $12,085 |
| Net income per share attributable to common stockholders: | ||
| Basic | $0.06 | $0.14 |
| Diluted | $0.02 | $0.05 |
| Weighted average shares used in calculating net income per share attributable to common stockholders: | ||
| Basic | 89,344,622 | 85,094,948 |
| Diluted | 103,180,037 | 102,293,526 |
| Other comprehensive income: | ||
| Net income from operations | $9,880 | $17,898 |
| Foreign currency translation adjustments | 2,636 | (1,460) |
| Comprehensive income from operations | 12,516 | 16,438 |
| Net income attributable to noncontrolling interest | 4,853 | 5,813 |
| Foreign currency translation adjustments attributable to noncontrolling interest | 818 | (507) |
| Comprehensive income attributable to noncontrolling interest | 5,671 | 5,306 |
| Comprehensive income attributable to common stockholders | $6,845 | $11,132 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.